Literature DB >> 6252514

Assumptions in the radiotherapy of glioblastoma.

F H Hochberg, A Pruitt.   

Abstract

In the light of advances in computerized tomography (CT), we have retrospectively evaluated the assumptions that underlie the radiation therapy of glioblastoma: (1) No neuroradiologic technique provides an accurate delineation of tumor bulk and location, (2) glioblastoma is commonly multicentric, and (3) a major source of therapeutic failure is recurrence beyond radiotherapy fields. 1. CT scans, performed on glioblastoma patients within 2 months of postmortem examination, defined both gross and microscopic tumor extent (within a 2-cm margin) in all but 6 of 35 patients evaluated. The major source of error was subependymal spread (four patients). 2. Multicentricity occurred in only 4% of untreated and 6% of treated (radiotherapy with or without chemotherapy) patients. All multicentric lesions were identified on CT scans. 3. Serial CT scans on 42 patients revealed that glioblastoma recurred within a 2-cm margin of the primary site in 90%. Occurrences outside this margin were accurately delineated by CT in all instances. Because most patients show recurrence within or in close proximity to the original site, current radiation doses would appear to be inadequate for therapy of the primary tumor. CT scan accuracy may permit smaller-field and higher-dose irradiation therapy for glioblastoma.

Entities:  

Mesh:

Year:  1980        PMID: 6252514     DOI: 10.1212/wnl.30.9.907

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  231 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies.

Authors:  A Boiardi; A Silvani; A Pozzi; L Fariselli; G Broggi; A Salmaggi
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  Boron neutron capture enhancement (BNCE) of fast neutron irradiation for glioblastoma: increase of thermal neutron flux with heavy material collimation, a theoretical evaluation.

Authors:  P Paquis; J P Pignol; M Lonjon; N Brassart; A Courdi; P Chauvel; P Grellier; M Chatel
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

4.  Estimation of tumor volume with fuzzy-connectedness segmentation of MR images.

Authors:  Gul Moonis; Jianguo Liu; Jayaram K Udupa; David B Hackney
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 5.  Gene therapy for glioblastoma: future perspective for delivery systems and molecular targets.

Authors:  A Shir; A Levitzki
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

6.  Large dose fraction radiotherapy in the treatment of glioblastoma.

Authors:  M Tamura; M Nakamura; H Kunimine; N Ono; A Zama; K Hayakawa; H Niibe
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

7.  Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.

Authors:  Mekhail Anwar; Annette M Molinaro; Olivier Morin; Susan M Chang; Daphne A Haas-Kogan; Sarah J Nelson; Janine M Lupo
Journal:  Radiat Res       Date:  2017-07-19       Impact factor: 2.841

8.  Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.

Authors:  Rong Shao; Ralph Francescone; Nipaporn Ngernyuang; Brooke Bentley; Sherry L Taylor; Luis Moral; Wei Yan
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

9.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

10.  Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.

Authors:  J Sherriff; J Tamangani; L Senthil; G Cruickshank; D Spooner; B Jones; C Brookes; P Sanghera
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.